La rivastigmine pourrait également ralentir la progression de la maladie d'Alzheimer

Translated title of the contribution: Analysis of outcome in retrieved droup-out patients in a rivastigmine versus placebo 26-weeks, Alzheimer disease trial

Martin Farlow, Steven Potkin, Barbara Koumaras, Jeffrey Veach, Dario Mirski

Research output: Contribution to journalShort survey

Translated title of the contributionAnalysis of outcome in retrieved droup-out patients in a rivastigmine versus placebo 26-weeks, Alzheimer disease trial
Original languageFrench
Pages (from-to)843-844
Number of pages2
JournalRevue de Geriatrie
Volume28
Issue number10
StatePublished - Dec 1 2003

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Farlow, M., Potkin, S., Koumaras, B., Veach, J., & Mirski, D. (2003). La rivastigmine pourrait également ralentir la progression de la maladie d'Alzheimer. Revue de Geriatrie, 28(10), 843-844.